The pathological features of Alzheimer’s disease (AD) are well described but little is known as to how both neurodegeneration and vascular changes might interact in causing cognitive impairment.
Objective:
The present study aims to investigate relationships between vascular and AD pathology in cognitively healthy and cognitively impaired individuals with a particular emphasis on those at intermediate Braak tau stages.
Methods:
We investigated the interplay between Braak tau stage and measures of vascular pathology as described by the vascular cognitive impairment neuropathology guidelines (VCING) in 185 brains from the Brains for Dementia Research programme and The University of Manchester Longitudinal Study of Cognition in Healthy Old Age. VCING asserts that at least one large (>10 mm) infarct, moderate/severe occipital leptomeningeal cerebral amyloid angiopathy, and moderate/severe arteriosclerosis in occipital white matter accurately predicts the contribution of cerebrovascular pathology to cognitive impairment.
Results:
We found that the extent of arteriosclerosis in the occipital white matter did not differ between cognitive groups at intermediate (III-IV) Braak stages whereas moderate/severe leptomeningeal occipital cerebral amyloid angiopathy was greater in cognitively impaired than normal individuals at Braak stage III-IV. This finding remained significant after controlling for effects of age, sex, CERAD score, Thal phase, presence/severity of primary age-related tauopathy, presence/severity of limbic-predominant age-related TDP43 encephalopathy and small vessel disease in basal ganglia.
Conclusion:
Interventions targeting cerebral amyloid angiopathy may contribute to delay the onset of cognitive impairment in individuals with intermediate Alzheimer’s type pathology.
MatthewsFE, BrayneC, LoweJ, McKeithI, WhartonSB, InceP (2009) Epidemiological pathology of dementia: Attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med6, e1000180.
2.
Neuropathology Group. Medical Research Council Cognitive Function and Aging Study (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet357, 169–175.
3.
SnowdenDA, Nun Study (2003) Healthy aging and dementia: Findings from the Nun Study. Ann Intern Med139, 450–454.
4.
BennettDA, SchneiderJA, ArvanitakisZ, WilsonRS (2012) Overview and findings from the religious orders study. Curr Alzheimer Res9, 628–645.
5.
Cambridge City over 75 Cohort Study (2005) Cambridge City over 75 Cohort Study, http://www.cc75c.group.cam.ac.uk. Accessed January 19, 2018.
6.
GelberRP, LaunerLJ, WhiteLR (2012) The Honolulu-Asia Aging Study: Epidemiologic and neuropathologic research on cognitive impairment. Curr Alzheimer Res9, 664–672.
7.
KukullWA, HigdonR, BowenJD, McCormickWC, TeriL, SchellenbergGD, van BelleG, JolleyL, LarsonEB (2002) Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol59, 1737–1746.
8.
National Institute on Ageing (2013) Baltimore Longitudinal Study of Ageing, https://www.blsa.nih.gov. Accessed January 19, 2018.
RabbittPMA, McInnesL, DiggleP, HollandF, BentN, AbsonV, PendletonN, HoranM (2004) The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age, 1983 through 2003. Aging Neuropsychol Cogn11, 245–279.
11.
RobinsonAC, DavidsonYS, HoranMA, PendletonN, MannDMA (2018) Pathological correlates of cognitive impairment in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. J Alzheimers Dis64, 483–496.
12.
RobinsonAC, Chew-GrahamS, DavidsonYS, HoranMA, RoncaroliF, MinshullJ, du PlessisD, PalP, PaytonA, PendletonN, MannDMA (2020) A comparative study of pathological outcomes in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age and Brains for Dementia Research Cohorts. J Alzheimers Dis73, 619–632.
SonnenJA, LarsonEB, CranePK, HaneuseS, LiG, SchellenbergGD, CraftS, LeverenzJB, MontineTJ (2007) Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol62, 406–413.
15.
XuerebJH, BrayneC, DufouilC, GertzH, WischikC, HarringtonC, Mukaetova-LadinskaE, McGeeMA, O’SullivanA, O’ConnorD, PaykelES, HuppertFA (2000) Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann N Y Acad Sci903, 490–496.
KulstadJJ, GreenPS, CookDG, WatsonGS, RegerMA, BakerLD, PlymateSR, AsthanaS, RhoadsK, MehtaPD, CraftS (2006) Differential modulation of plasma beta amyloid by insulin in patients with Alzheimer disease. Neurology66, 1506–1510.
19.
MufsonEJ, IkonomovicMD, CountsSE, PerezSE, Malek-AhmadiM, ScheffSW, GinsbergSD (2016) Molecular and cellular pathophysiology of preclinical Alzheimer’s disease. Behav Brain Res311, 54–69.
20.
Malek-AhmadiM, PerezSE, ChenK, MufsonEJ (2020) Braak stage, cerebral amyloid angiopathy, and cognitive decline in early Alzheimer’s disease. J Alzheimers Dis74, 189–197.
21.
SkrobotOA, AttemsJ, EsiriM, HortobágyiT, IronsideJW, KalariaRN, KingA, LammieGA, MannD, NealJ, Ben-ShlomoY, KehoePG, LoveS (2016) Vascular cognitive impairment neuropathology guidelines (VCING): The contribution of cerebrovascular pathology to cognitive impairment. Brain139, 2957–2969.
22.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBT; National Institute on Aging; Alzheimer’s Association (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol123, 1–11.
23.
McKeithIG, GalaskoD, KosakaK, PerryEK, DicksonDW, HansenLA, SalmonDP, LoweJ, MirraSS, ByrneEJ, LennoxG, QuinnNP, EdwardsonJA, IncePG, BergeronC, BurnsA, MillerBL, LovestoneS, CollertonD, JansenEN, BallardC, de VosRA, WilcockGK, JellingerKA, PerryRH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology47, 1113–1124.
24.
McKeithIG, DicksonDW, LoweJ, EmreM, O’BrienJT, FeldmanH, CummingsJ, DudaJE, LippaC, PerryEK, AarslandD, AraiH, BallardCG, BoeveB, BurnDJ, CostaD, Del SerT, DuboisB, GalaskoD, GauthierS, GoetzCG, Gomez-TortosaE, HallidayG, HansenLA, HardyJ, IwatsuboT, KalariaRN, KauferD, KennyRA, KorczynA, KosakaK, LeeVM, LeesA, LitvanI, LondosE, LopezOL, MinoshimaS, MizunoY, MolinaJA, Mukaetova-LadinskaEB, PasquierF, PerryRH, SchulzJB, TrojanowskiJQ, YamadaM; Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology65, 1863–1872.
MackenzieIR, NeumannM, BaborieA, SampathuDM, du PlessisD, JarosE, PerryRH, TrojanowskiJQ, MannDM, LeeVM (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol122, 111–113.
28.
DicksonDW, BergeronC, ChinSS, DuyckaertsC, HoroupianD, IkedaK, JellingerK, LantosPL, LippaCF, MirraSS, TabatonM, VonsattelJP, WakabayashiK, LitvanI; Office of Rare Diseases of the National Institutes of Health (2002) Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol61, 935–946.
TrojanowskiJQ, ReveszT; Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol33, 615–620.
31.
BraakH, BraakE (1998) Argyrophilic grain disease: Frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm105, 801–819.
WenhamPR, PriceWH, BlandellG (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet337, 1158–1159.
36.
MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, van BelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41, 479–486.
37.
ThalDR, RübU, OrantesM, BraakH (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology58, 1791–1800.
38.
YouY, PerkinsA, CisternasP, MunozB, TaylorX, YouY, GarringerHJ, OblakAL, AtwoodBK, VidalR, Lasagna-ReevesCA (2019) Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy. Acta Neuropathol Commun7, 26.
39.
DufouilC, ChalmersJ, CoskunO, BesançonV, BousserMG, GuillonP, MacMahonS, MazoyerB, NealB, WoodwardM, Tzourio-MazoyerN, TzourioC; PROGRESS MRI Substudy Investigators (2005) Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) magnetic resonance imaging substudy. Circulation112, 1644–1650.
40.
FirbankMJ, WisemanRM, BurtonEJ, SaxbyBK, O’BrienJT, FordGA (2007) Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure. J Neurol254, 713–721.
41.
HerzigMC, Van NostrandWE, JuckerM (2006) Mechanism of cerebral beta-amyloid angiopathy: Murine and cellular models. Brain Pathol16, 40–54.
42.
NicollJAR, YamadaM, FrackowiakJ, Mazur KoleckaB, WellerRO (2004) Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer’s disease. Pro-CAA position statement. Neurobiol Aging25, 589–597.
43.
WellerRO, SubashM, PrestonSD, MazantiI, CarareRO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol18, 253–266.
44.
WellerRO, MasseyA, NewmanTA, HutchingsM, KuoYM, RoherAE (1998) Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer’s disease. Am J Pathol153, 725–733.
